147 related articles for article (PubMed ID: 12583823)
1. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.
Eggermont AM; ten Hagen TL
Curr Oncol Rep; 2003 Mar; 5(2):79-80. PubMed ID: 12583823
[No Abstract] [Full Text] [Related]
2. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models.
Eggermont AM
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1357-70. PubMed ID: 8854755
[No Abstract] [Full Text] [Related]
3. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
Fraker DL; Alexander HR
Important Adv Oncol; 1994; ():179-92. PubMed ID: 8206489
[No Abstract] [Full Text] [Related]
4. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
[TBL] [Abstract][Full Text] [Related]
5. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic perfusion of extremities for melanoma and soft tissue sarcomas.
Stehlin JS; Giovanella BC; de Ipolyi PD; Muenz LR; Anderson RF; Gutierrez AA
Recent Results Cancer Res; 1977; (59):171-85. PubMed ID: 408886
[No Abstract] [Full Text] [Related]
7. Hyperthermic isolated limb perfusion in the management of extremity sarcoma.
Hoekstra HJ; van Ginkel RJ
Curr Opin Oncol; 2003 Jul; 15(4):300-3. PubMed ID: 12874508
[TBL] [Abstract][Full Text] [Related]
8. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities.
Grünhagen DJ; de Wilt JH; ten Hagen TL; Eggermont AM
Nat Clin Pract Oncol; 2006 Feb; 3(2):94-103. PubMed ID: 16462850
[TBL] [Abstract][Full Text] [Related]
9. [Value of isolation-perfusion of the limbs in melanomas and sarcomas].
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477
[No Abstract] [Full Text] [Related]
10. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
[TBL] [Abstract][Full Text] [Related]
11. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
Hohenberger P; Bida B; Schlag PM
Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
[No Abstract] [Full Text] [Related]
12. [Hyperthermic-antiblastic perfusion in the treatment of tumor of the extremities].
Di Filippo F; Cavaliere F; Anzà M; Garinei R; Rossi CR; Deraco M; Perri P; Botti C; Cigna E
Suppl Tumori; 2002; 1(3):S35-7. PubMed ID: 12415785
[No Abstract] [Full Text] [Related]
13. Efficiency of recombinant human TNF in human cancer therapy.
Lejeune FJ; Liénard D; Matter M; Rüegg C
Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
15. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].
Hohenberger P; Haier J; Kettelhack C; Schulze G; Schlag PM
Chirurg; 1997 Sep; 68(9):914-20. PubMed ID: 9410682
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience.
Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR
Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883
[TBL] [Abstract][Full Text] [Related]
18. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
Haier J; Hohenberger P; Beck K; Schlag PM
Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
[TBL] [Abstract][Full Text] [Related]
19. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V
Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120
[TBL] [Abstract][Full Text] [Related]
20. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
